Pediatric Dermatology

Update on Pediatric Psoriasis, Part 2: Therapeutic Management

Silverberg NB

Pediatric psoriasis is an autoimmune diathesis with a complex immunologic basis. It is associated with extensive psychological morbidity and should be treated rapidly and effectively to limit psychologic effects on children. The most common trigger in childhood is upper respiratory tract infection. Once disease has occurred, treatment is based on severity and presence of joint involvement. Topical therapies include corticosteroids and calcipotriene. UV light, systemic retinoids, and cyclosporine remit cutaneous psoriatic lesions. Methotrexate sodium and etanercept benefit both skin and joint manifestations of psoriasis. Concern for psychological symptoms and psychological growth is needed in treating pediatric patients with psoriasis vulgaris.


 

Recommended Reading

Generic Biologics' Safety Questioned as Approval Process Stalls
Psoriasis Collection
Vitamin D - Myths or Truths?
Psoriasis Collection
Adalimumab Found Safe for Psoriatic Diseases
Psoriasis Collection
Cyclosporine Often Best Option for Pediatric Pustular Psoriasis Flare
Psoriasis Collection
Bosentan Reduced Occurrence of Digital Ulcers in Systemic Sclerosis
Psoriasis Collection
Focus on the Psychosocial Impacts of Psoriasis in Women
Psoriasis Collection
Dressing Up Psoriasis
Psoriasis Collection
TNF Antagonists in Rheumatic Patients Linked to Increased Hospitalization for Varicella Zoster
Psoriasis Collection
Improvement in Psoriasis During Rituximab Therapy for Mixed Cryoglobulinemia Type II
Psoriasis Collection
Update on Pediatric Psoriasis, Part 1: Clinical Features and Demographics
Psoriasis Collection